Satoshi Yuki
Overview
Explore the profile of Satoshi Yuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sawada K, Yuki S
Gan To Kagaku Ryoho
. 2023 Dec;
50(11):1175-1181.
PMID: 38056869
No abstract available.
12.
Harada K, Yuki S, Kawamoto Y, Nakamura T, Kaneko S, Ishida K, et al.
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231216090.
PMID: 38033418
The Neo phenomenon is defined as the conversion of tumor status from mutant-type (MT) to wild-type (WT) after systemic chemotherapy in metastatic colorectal cancer (mCRC). Cetuximab, an anti-epidermal growth factor...
13.
Kajiwara T, Nishina T, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958346
The treatment strategies and prognoses of patients with metastatic colorectal cancer (CRC) differ according to the sidedness of the primary tumor. gain-of-function (GOF) and non-GOF variants have been reported to...
14.
Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al.
Cancer Med
. 2023 Aug;
12(18):18702-18716.
PMID: 37641470
Background: Several biomarkers have been established for metastatic colorectal cancer (mCRC). We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first-line (1L) treatment...
15.
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, et al.
Br J Cancer
. 2023 Aug;
129(6):1032-1039.
PMID: 37532830
Background: Although nivolumab has a high efficacy, reliable biomarkers are needed to predict the efficacy. We evaluated the nivolumab efficacy according to the TP53 mutation in advanced gastric cancer patients...
16.
Inagaki C, Matoba R, Yuki S, Shiozawa M, Tsuji A, Inoue E, et al.
Future Oncol
. 2023 Jul;
19(17):1165-1174.
PMID: 37458152
For V600E-mutated metastatic colorectal cancer (mCRC), the BEACON phase 3 trial showed survival benefit of triplet therapy with cetuximab (anti-EGFR antibody), encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) as well...
17.
Yamazaki K, Yuki S, Oki E, Sano F, Makishima M, Aoki K, et al.
Future Oncol
. 2023 Jun;
19(39):2569-2583.
PMID: 37387237
Physicians determine the treatment regimen for metastatic colorectal cancer on a case-by-case bases, according to the individual disease characteristics. We retrospectively compared the baseline characteristics and efficacies of first-line treatment...
18.
Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, et al.
Cancer Sci
. 2023 May;
114(8):3385-3395.
PMID: 37208840
Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not...
19.
Nakamura Y, Yamashita R, Okamoto W, Komatsu Y, Yuki S, Ueno M, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200653.
PMID: 36996376
Purpose: Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic profiling program in advanced gastrointestinal cancers using a...
20.
Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, et al.
Int J Clin Oncol
. 2023 Mar;
28(5):654-663.
PMID: 36856908
Background: Oncogenic mutations in BRAF genes are found in approximately 5-10% of colorectal cancers. The majority of BRAF mutations are located within exons 11-15 of the catalytic kinase domains, with...